97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
HUMANIZED ANTIBODIES AGAINST PD-L1
#1202CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF
#1203RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY
#1204Antibodies against signal-regulatory protein alpha and methods of use
#1205ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS
#1206DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES
#1207ANTIBODIES
#1208Activatable Multi-Specific Antigen Binding Protein Complexes
#1209COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER
#1210ANTI-PD-L1 SINGLE-DOMAIN ANTIBODY AND DERIVATIVES AND USE THEREOF
#1211BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF
#1212METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#1213Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
#1214Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same
#1215USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY IN A COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#1216COMBINATION OF CTLA4 AND PD1/PDL1 ANTIBODIES FOR TREATING CANCER
#1217ANTIBODY-INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
#1218IMMUNE MICROBUBBLE COMPLEX, AND USE THEREOF
#1219IL-15-based molecules and methods of use thereof
#1220METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER
#1221COMBINATION THERAPY WITH A MEK INHIBITOR, A PD-1 AXIS INHIBITOR, AND A VEGF INHIBITOR
#1222ANTI-B7-H3 ANTIBODY AND METHODS OF USE THEREOF
#1223ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
#1224Antibodies binding PD-L1 and uses thereof
#1225USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY IN A NEOADJUVANT COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#1226TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA
#1227COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF BLADDER CANCER
#1228Treating and preventing microbial infections
#1229ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
#1230ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
#1231Anti-SIRPa antibodies and methods of use thereof
#1232FLT3 ligand fusion proteins and methods of use
#1233MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF
#1234PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY
#1235TREATING AND PREVENTING MICROBIAL INFECTIONS
#1236Primary NK CAR Constructs And Methods
#1237TARGETED CHIMERIC PROTEINS AND USES THEREOF
#1238Anti-SIRPa antibodies and their therapeutic applications
#1239ANTIBODIES AND BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER
#1240Dosage regimes for the administration of an anti-CD19 ADC
#1241Engineered immunostimulatory bacterial strains and uses thereof
#1242ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF
#1243ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
#1244DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY
#1245Checkpoint blockade and microsatellite instability
#1246Multifunctional protein molecules comprising decorin and use thereof
#1247Constrained conditionally activated binding proteins
#1248Constrained conditionally activated binding proteins
#1249BISPECIFIC ANTIBODY TARGETING OF T REGULATORY CELLS FOR TREATMENT OF INFLAMMATORY CONDITIONS
#1250METHODS OF TREATING CANCER BY TARGETING COLD TUMORS
#1251COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
#1252Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders
#1253NOVEL IL-10 VARIANT PROTEIN AND USE THEREOF
#1254COMPOSITION FOR ENHANCING EFFECT OF ANTIBODY DRUG
#1255COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT
#1256METHODS OF IDENTIFYING A SUBJECT SUITABLE FOR AN IMMUNO-ONCOLOGY (I-O) THERAPY
#1257Treating and preventing microbial infections
#1258Checkpoint blockade and microsatellite instability
#1259ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#1260ANTI-IL-27 ANTIBODIES AND USES THEREOF
#1261CD80 and CD86 Binding Protein Compositions and Uses Thereof
#1262CD80 and CD86 binding protein compositions and uses thereof
#1263METHODS OF USING PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
#1264Oncolytic adenovirus and checkpoint inhibitor combination therapy
#1265Bispecific Antibodies for Activation of Immune Cells
#1266Anti-B7-H4 antibodies and immunoconjugates
#1267ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#1268A NOVEL ANTI-PD-L1 ANTIBODY AND USE THEREOF
#1269FORMULATION COMPRISING ANTI-CD47/PD-L1 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF
#1270BISPECIFIC BINDING PROTEINS AND USES THEREOF
#1271ANTI-CD33 ANTIBODIES FOR TREATING CANCER
#1272METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION
#1273PDL1 POSITIVE NK CELL CANCER TREATMENT
#1274PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTITUMOR EFFECT BY IMMUNE CHECKPOINT INHIBITOR
#1275IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
#1276NTRK FUSION MOLECULES AND USES THEREOF
#1277ANTI-PD-L1 NANOBODY AND FC FUSION PROTEIN AND APPLICATION THEREOF
#1278CD63 AGONIST-RELATED METHODS AND COMPOSITIONS
#1279Anti-4-1BB antibody and use thereof
#1280CSF1R/CCR2 MULTISPECIFIC ANTIBODIES
#1281CD3 antibody and pharmaceutical use thereof
#1282ANTI-B7-H3 ANTIBODIES
#1283MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN DIMER AND APPLICATION THEREOF
#1284Antibody Compositions and Methods of Use Thereof
#1285ADMINISTRATION OF SUMO-ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS
#1286COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES
#1287Cancer stratification and treatment based on Inhibition of NOD-2
#1288ANTI-GAL9 IMMUNE-INHIBITING BINDING MOLECULES
#1289ANTI-PD-L1 ANTIBODY
#1290TRIPLE-CHAIN ANTIBODY, METHOD FOR PREPARATION AND USE THEREOF
#1291ASSOCIATION OF POLYCLONAL ANTIBODIES AND ANTI-PD1 OR ANTI-PDL1 ANTIBODIES FOR TH TREATMENT OF CANCER
#1292Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
#1293Anti-ILT3 antibodies and antibody drug conjugates
#1294NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE
#1295AFFINITY MATURATED TAG72 SPECIFIC SINGLE CHAING ANTIBODIES
#1296DOSING REGIMEN OF AVELUMAB FOR THE TREATMENT OF CANCER
#1297ANTI-PD-L1/ANTI-LAG-3 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
#1298HIV vaccines and methods of using
#1299METHODS AND COMPOSITIONS FOR TREATING CANCER
#1300METHOD OF TREATMENT
#1301BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGFß AND USE THEREOF
#1302Agents modulating beta-catenin functions and methods thereof
#1303ANTIBODY-DRUG CONJUGATES WITH IMMUNE-MEDIATED THERAPY AGENTS
#1304COMPOSITIONS COMPRISING ALBUMIN-FMS-LIKE TYROSINE KINASE 3 LIGAND FUSION PROTEINS AND USES THEREOF
#1305USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS
#1306FC-MODIFIED BIOLOGICALS FOR LOCAL DELIVERY TO COMPARTMENTS, IN PARTICULAR TO THE CNS
#1307COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
#1308Efflux Pump-Cancer Antigen Multi-Specific Antibodies and Compositions, Reagents, Kits and Methods Related Thereto
#1309BISPECIFIC FUSION PROTEIN AND APPLICATION THEREOF
#1310Combination Therapy for the Treatment of Cancer
#1311Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#1312METHODS AND COMPOSITIONS FOR TREATING CANCER
#1313CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION
#1314METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG
#1315COMBINED PHARMACEUTICAL COMPOSITION
#1316Fc-MODIFIED BIOLOGICALS FOR LOCAL DELIVERY TO COMPARTMENT, IN PARTICULAR TO THE CNS
#1317Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector
#1318ANTIBODIES AGAINST PROGRAMMED DEATH-LIGAND 1 AND USES THEREOF
#1319METHODS OF TREATING TUMOR
#1320Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#1321Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
#1322Combination therapy
#1323BINDING MOLECULES BINDING PD-L1 AND LAG-3
#1324Genetically engineered dual-targeting chimeric antigen receptor and use thereof
#1325METHODS OF ANTI-TUMOR THERAPY
#1326Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
#1327METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE
#1328Ionic channel modulation as a method for treating tumors through inflammasome activation
#1329ANTI PD-L1 ANTIBODY AND USE THEREOF
#1330CD8 BINDING AGENTS
#1331Models and Methods Useful for the Treatment of Serrated Colorectal Cancer
#1332TARGETED DELIVERY OF IMMUNE-MODULATING VHH AND VHH-FUSION PROTEIN
#1333Methods of classifying response to immunotherapy for cancer
#1334COMBINATIONS OF ANTI-ILDR2 ANTIBODIES AND PD-1 ANTAGONISTS
#1335Methods of sensitizing cancer to immunotherapy
#1336Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
#1337BISPECIFIC ANTIBODIES AND USES THEREOF
#1338METHODS AND COMPOSITIONS FOR REDUCING METASTASES
#1339COMBINED PHARMACEUTICAL COMPOSITION
#1340TIME TO RESOLUTION OF AXITINIB-RELATED ADVERSE EVENTS
#1341METHODS OF USING MONOCLONAL ANTIBODIES TARGETING EPITOPES OF ASPH
#1342ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
#1343DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#1344CD80 variant immunomodulatory proteins and uses thereof
#1345Anti-B7-H4 antibodies and immunoconjugates
#1346Anti-CD112R compositions and methods
#1347Combination Immunotherapy For The Treatment of Cancer
#1348ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS
#1349COMPOSITION AND PROCESS FOR PREPARING VACCINE
#1350COMPOSITIONS AND METHODS OF TREATING CANCER
#1351Modulation of molecular markers using S-equol
#1352Antibodies specific to glycosylated PD-L1 and methods of use thereof
#1353COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRAS ASSOCIATED DISEASES OR DISORDERS
#1354IMMUNOSTIMULATORY BACTERIA DELIVERY PLATFORMS AND THEIR USE FOR DELIVERY OF THERAPEUTIC PRODUCTS
#1355CD80 variant immunomodulatory proteins and uses thereof
#1356Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition
#1357BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#1358Chemically-Locked Bispecific Antibodies
#1359Anti-PD-L1 antibodies and variants
#1360ANTI-VISTA ANTIBODIES AND FRAGMENTS
#1361VISTA-BINDING ANTIBODIES AND USES THEREOF
#1362Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
#1363Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors
#1364DRUG DELIVERY FOR COMBINATION OF EPIGENETIC MODULATION AND IMMUNE CHECKPOINT BLOCKADE
#1365Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
#1366Antibodies and variants thereof against PD-L1
#1367BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28
#1368PDLIM2 AS A BIOMARKER FOR CANCER AND AS AN ANTI-CANCER TREATMENT TARGET
#1369METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#1370ONCOLYTIC VIRUSES TARGETING STAT3
#1371ONCOLYTIC VIRUSES TARGETING STAT3
#1372NOVEL ANTI-PD-L1 ANTIBODY AND USES THEREOF
#1373Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
#1374COMBINATION OF PD-1/PD-L1 INHIBITORS AND TARGETED THORIUM CONJUGATES
#1375DARC EXPRESSION AS PROGNOSTICATOR OF IMMUNOTHERAPY OUTCOMES
#1376ANTI-PD-L1 ANTIBODIES AND USES THEREOF
#1377Anti-CD28 compositions
#1378Anti-B7-H3 antibody
#1379MODULATION OF DENDRITIC CELL LINEAGES
#1380BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#1381Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody
#1382COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR
#1383Humanized anti-PD-L1 antibodies
#1384Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
#1385BIFUNCTIONAL MOLECULES WITH IL-7 ACTIVITY
#1386Immunoswitch nanoparticles for reprogrammed T cell responses
#1387CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY
#1388WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF
#1389Multivalent and multispecific OX40-binding fusion proteins
#1390NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF
#1391METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
#1392METHODS AND COMPOSITIONS FOR THE MODULATION OF OPIOID SIGNALING IN THE TUMOR MICROENVIRONMENT
#1393ANTI-NEUROPILIN ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
#1394Therapeutic binding molecules
#1395MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOF
#1396Anti-CD28 compositions
#1397NOVEL ICOS ANTIBODIES AND TUMOR-TARGETED ANTIGEN BINDING MOLECULES COMPRISING THEM
#1398METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS
#1399COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR
#1400BINDER AGAINST PROGRAMMED DEATH-LIGAND AND APPLICATION THEREOF
#1401TIM-3 ANTIBODIES AND COMBINATIONS WITH OTHER CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER
#1402ANTI-B7S1 POLYPEPTIDES AND THEIR USE
#1403BI-AND TRI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF
#1404Methods for modulating an immune response
#1405Anti-PD-L1 diabodies and the use thereof
#1406TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY
#1407TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION
#1408ANTICANCER COMPOSITIONS COMPRISING IMMUNE CHECKPOINT INHIBITORS
#1409ANTI-TIM-3 ANTIBODIES
#1410USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER
#1411Therapeutic Cancer Immune Modulation by Treatment with mTOR Inhibitors
#1412THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#1413Compositions and Methods for Treating Late Stage Lung Cancer
#1414ANTI-PD-L1 ANTIBODY AND USE THEREOF
#1415ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#1416BTN3A binding proteins and uses thereof
#1417Humanized anti-human PD-L1 monoclonal antibody and preparation method therefor and use thereof
#1418Antibodies binding to vista at acidic pH
#1419METHODS OF ADMINISTERING ANTI-TIM-3 ANTIBODIES
#1420BIVALENT BISPECIFIC ANTIBODY AND PREPARTION METHOD THEREOF, CODING GENE, HOST CELL AND COMPOSITION
#1421COMPOSITIONS AND METHODS OF TREATING MELANOMA
#1422Combination therapies for the treatment of cancer
#1423Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
#1424SPHERICAL NUCLEIC ACID TLR9 AGONISTS
#1425ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#1426THERAPY
#1427GENETICALLY MODIFIED NK-92 CELLS HAVING A SAFETY SWITCH
#1428COMBINATION OF A SK2 INHIBITOR AND AN INHIBITOR OF A CHECKPOINT PATHWAY, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
#1429Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
#1430Combinations of Cabozantinib and Atezolizumab to Treat Cancer
#1431Anti-PD-L1 Binding Proteins and Methods of Use Thereof
#1432Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof
#1433CD3-binding molecules capable of binding to human and non-human CD3
#1434Checkpoint blockade and microsatellite instability
#1435IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#1436IMMUNOMODULATORY & ONCOLYTIC MINICELLS AND METHODS OF USE
#1437USING CATEQUENTINIB (ANLOTINIB) COMBINING WITH STANDARD CHEMOTHERAPY OR IMMUNOTHERAPY IN SEQUENTIAL ORDER FOR THE CANCER TREATMENT
#1438TETRAVALENT MULTISPECIFIC ANTIBODIES
#1439ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137
#1440Antibodies
#1441VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
#1442Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
#1443Antibody molecules that bind CD137 and OX40
#1444Humanized and affinity matured antibodies to FcRH5 and methods of use
#1445Antibody-drug conjugates comprising anti-B7-H3 antibodies
#1446BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#1447CD73 BLOCKING ANTIBODIES
#1448METHODS OF TREATING CANCER WITH AN ANTI-PD-L1 ANTIBODY
#1449METHODS OF TREATING TUMOR
#1450INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS
#1451INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS
#1452INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS
#1453INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS
#1454Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
#1455REGULATABLE CELL SURFACE RECEPTORS AND RELATED COMPOSITIONS AND METHODS
#1456USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY
#1457Anti PD-L1 Conjugates for Treating Tumors
#1458FOXP1-ABLATED CHIMERIC CELLS
#1459Bispecific antibodies and uses thereof
#1460Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
#1461Bifunctional molecules for lysosomal targeting and related compositions and methods
#1462Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
#1463Immunosuppresive agent
#1464Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
#1465IDENTIFICATION OF GUT BACTERIA THAT PROMOTE AN ANTI-TUMOR RESPONSE TO IMMUNOTHERAPY
#1466Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
#1467Bispecific antibodies and uses thereof
#1468Agonistic CD28 antigen binding molecules targeting Her2
#1469Anti-TNFR2 antibody and use thereof
#1470TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOR
#1471Therapeutic antibodies and their uses
#1472Combination Therapy for Cancer
#1473Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
#1474TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
#1475Combination therapy with an anti-CD25 antibody-drug conjugate
#1476Antibody drug conjugates (ADCS) having enzymatically cleavable groups
#1477METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY
#1478METHODS AND COMPOSITIONS FOR TREATING CANCER
#1479COMBINATION TREATMENT OF HIV INFECTIONS
#1480Monoclonal antibodies against IgV domain of B7-H3 and uses thereof
#1481PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND EITHER ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER
#1482Combination therapy with notch and PD-1 or PD-L1 inhibitors
#1483COMPOSITIONS AND METHODS OF ENHANCING IMMUNOTHERAPIES
#1484COMBINATION ANTI-CANCER PRODUCTS AND METHODS
#1485METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#1486GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF
#1487COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#1488Anti-PD-L1/VEGF bifunctional antibody and use thereof
#1489Anti-PD-L1 antibodies and methods of making and using thereof
#1490METHODS FOR TREATING IMMUNE RELATED OCULAR DISORDERS
#1491Multi-specific antibodies and methods of making and using thereof
#1492Antitumor effect potentiator
#1493Bispecific antibody
#1494SYNERGISTIC COMBINATIONS OF METHIONINE DEPLETION AGENTS AND IMMUNE CHECKPOINT MODULATORS
#1495BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION
#1496COMBINATION THERAPY FOR TREATMENT OF DISEASE
#1497Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy
#1498IMMUNE CHECKPOINT INHIBITOR COMBINATIONS
#1499NANOPLEXED POLY(I:C) FORMULATIONS AND USES THEREOF
#1500Antibodies targeting CD137 and methods of use thereof